Scott Rocklage is currently the Managing Partner of 5AM Ventures. He was placed in that position in 2004. Just a year prior, he started out as the Venture Partner for the company. He has a long background of experience. He has been in the healthcare field for more than 20 years. He is skilled in healthcare management. His leadership skills and responsibilities led him to be approved successfully by three U.S. New Drug Applications by the Food and Drug Association (FDA), known as the Omniscan, Teslascan and Cubicin. He has held the role as the Chairman and CEO of Cubist Pharmaceuticals, President and the Chief Executive Officer of Nycomed Salutar. He also served as the President, Chief Executive Officer, and Chairman of Nycomed Interventional. He has been in numerous positions at Salutar and Catalytica. He was the Chief Executive Officer at EPIRUS Biopharmaceuticals, Inc. from May 2016 until July 2016 and served as its Acting Chief Executive Officer around the same time. He served as the Chief Executive Officer and President at Amersham Health. Scott Rocklage has had a steady and successful career in leadership.
Scott Rocklage is an active member of many different boards. He currently serves as the Board Chairman of Achaogen, Relypsa and Semprus. He is also on the Boards of WaveRx, Pulmatrix and Variation, and the Board of Associates at the Whitehead Institute. Scott Rocklage was previously the Executive Chairman of Ilypsa, which is taken over by Amgen, and Miikana, taken over by EntreMed.
Rocklage has a huge educational background. He received his Bachelor of Science degree in Chemistry from the University of California, Berkeley. He didn’t stop there. He then obtained his PhD in Chemistry from the Massachusetts Institute of Technology. He did his research in the laboratory named after the Noble Prize winner, Richard R. Schrock.
Scott Rocklage has invented and also co-invented over 30 U.S. patents and has over 100 publications. Scott Rocklage is located in the Waltham, MA office.